7 Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by West Midlands Health Technology Assessment Collaboration.

Burls A, Yaser A, Juarez-Garcia A et al (2006). Oral naltrexone as a treatment for relapse prevention in formerly opioid dependent drug users – a systematic review and economic evaluation. West Midlands Health Technology Assessment Collaboration.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and appraisal consultation document (ACD). Consultee organisations have the opportunity to appeal against the final appraisal determination (FAD).

I) Manufacturers/sponsors:

Bristol-Myers Squibb Pharmaceuticals Ltd

II) Professional/specialist and patient/carer groups:

  • Addaction

  • Addiction Recovery Foundation


  • Alliance (formerly the Methadone Alliance)

  • Association of Nurses in Substance Abuse (ANSA)

  • British Association for Psychopharmacology

  • Families Anonymous

  • Federation of Drug and Alcohol Professionals

  • Lifeline

  • National Drug Prevention Alliance

  • National Pharmaceutical Association

  • Pharmaceutical Services Negotiating Committee

  • Rehabilitation for Addicted Prisoners Trust (RAPt)

  • Release

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Physicians

  • Royal College of Physicians of Edinburgh

  • Royal College of Psychiatrists

  • Royal Pharmaceutical Society

  • Specialist Clinical Addiction Network (SCAN)

  • Substance Misuse Management in General Practice (SMMGP)

  • UK Harm Reduction Alliance

Turning Point

III) Consultee (others)

  • Department of Health

  • East Leeds PCT

  • Great Yarmouth PCT

Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • Action on Addiction

  • British National Formulary

  • Centre for Research on Drugs and Health Behaviour (Imperial College)

  • Department of Addictive Behaviour (St George's Hospital Medical School)

  • DrugScope

  • Drugs Misuse – Psychosocial Guidelines Development Group

  • Drugs Misuse – Detoxification Guidelines Development Group

  • HM Prison Service

  • Independent Drug Monitoring Unit (IDMU)

  • National Addiction Centre (Institute of Psychiatry)

  • National Coordinating Centre for Health Technology Assessment

  • National programme on substance abuse deaths, St George's Hospital Medical School

  • National Treatment Agency for Substance Misuse (NTA)

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Society for the Study of Addiction

West Midlands Health Technology Assessment Collaboration

C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on naltrexone for the management of opioid dependence by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Chris Ford, GP Clinical Lead, nominated by Substance Misuse Management in General Practice (SMMGP) – clinical specialist

  • Dr Judith Myles, Consultant Psychiatrist, nominated by Royal College of Psychiatrists – clinical specialist

  • Dr Duncan S Raistrick, Consultant in Addiction Psychiatry, nominated by Specialist Clinical Addiction Network (SCAN) – clinical specialist

  • Mr Peter McDermott, nominated by The Alliance – patient expert

  • Ms Moya Pinson, nominated by Release – patient expert

Mr Gary Sutton, Head of Drug Advice Team, nominated by Release – patient expert